Sunovion gets Canadian approval for Aptiom to treat partial-onset seizures
The company said that Aptiom is not indicated for use in patients under 18 years of age. The approval is based on three Phase III randomized, double-blind, placebo-controlled,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.